LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of lung cancer, a
LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably,
An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ brains, the company reported Wednesday, adding to
LONDON — It hasn’t even been a year since Pfizer closed its $43 billion acquisition of Seagen — one of the biggest biopharma deals in
LONDON — A coworking space surrounded by the crush of traffic around King’s Cross station is perhaps not the most glamorous digs. But as the
LONDON — For the second time in a matter of months, the U.K.’s cost-effectiveness watchdog has said the limited benefits of a newly approved Alzheimer’s
CVS Health has replaced Karen Lynch with David Joyner as CEO, it said Friday, part of an attempt to turn the struggling company around. Joyner
Barney Graham, who for decades helped lead U.S. vaccine development efforts, said Wednesday that the lack of cooperation among U.S. agencies is hindering the country’s
LONDON — The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals, which is developing treatments for neurological diseases, in a deal worth
LONDON — A trio of scientists who opened new doors in our understanding of the structure of proteins — the fundamental building blocks of biology